# US 2019/0314433 A1 · Composition for the Prevention and/or Treatment of Cardiovascular Diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314433 A1
- Document ID: US20190314433A1
- Status: Published application
- Kind: A1
- Application number: 16/347,613
- Filed: 2017-11-03
- Published: 2019-10-17
- Earliest claimed: 2016-11-04
- Assignees: Groupe Santé Devonian Inc.
- Applicants: Groupe Santé Devonian Inc.
- Inventors: André P. Boulet; Theophilus J. Gana; Nathalie Boucher
- Web page: https://patentgrep.com/patent/US20190314433A1

## CPC

- A61K 36/21: Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
- A61K 9/0031: {Rectum, anus}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/015: carbocyclic
- A61K 31/065: Diphenyl-substituted acyclic alcohols
- A61K 31/409: having four such rings, e.g. porphine derivatives, bilirubin, biliverdine (hemin, hematin A61K31/555)
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 39/06: Free radical scavengers or antioxidants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There is provided the use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of cardiovascular diseases, and method for the treatment thereof. The cardiovascular diseases (CVD) may comprise several diseases associated with inflammation of the heart or arteries and include coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack), atherosclerosis, stroke, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, and venous thrombosis.

## Claims

### Claim at position 1

-39. (canceled)

### Claim 40

A method for treating cardiovascular diseases (CVD) in a subject in need thereof, comprising administering to said subject an effective amount of a thylakoid extract comprising purified functional photosynthetic pigments in their thylakoid membrane environment, particularly in admixture with a physiologically acceptable carrier.

### Claim 41 (depends on 40)

The method of claim 40, wherein said extract is stabilized in a medium comprising less than 10% of electron donor.

### Claim 42 (depends on 41)

The method of claim 41, wherein said medium comprises less than 10% of water.

### Claim 43 (depends on 40)

The method of claim 40, wherein said extract is for oral administration.

### Claim 44 (depends on 40)

The method of claim 40, wherein said extract is formulated for parenteral administration.

### Claim 45 (depends on 40)

The method of claim 40, wherein said extract is formulated intra-cardiac administration immediately after a heart attack.

### Claim 46 (depends on 40)

The method of claim 40, wherein said extract is formulated intra-cardiac administration up to 24 hours after a heart attack.

### Claim 47 (depends on 40)

The method of claim 40, wherein said CVD is selected from: angina, stroke, myocardial/cerebral infraction, atherosclerosis, bypass surgery, ischemia, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, and venous thrombosis.

### Claim 48 (depends on 47)

The method of claim 47, wherein said CVD is angina, stroke, myocardial infraction, ischemia, venous thrombosis and atherosclerosis.

### Claim 49 (depends on 40)

The method of claim 40, wherein the extract is present in an amount achieving about 0.00005 to 500 mg per Kg of subject's body weight.

### Claim 50 (depends on 49)

The method of claim 49, wherein said amount of extract is about 0.05 to about 10 mg per Kg of subject's body weight.

### Claim 51 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 40 to 50, wherein the extract is in a dosage selected from: about 125 mg, about 200 mg, about 250 mg, about 500 and 1000 mg per day

### Claim at position 14

-57. (canceled)

### Claim 58

A method for decreasing a baseline level of blood CRP or blood hsCRP in a subject in need thereof, comprising administering to said subject an effective amount of a thylakoid extract comprising purified functional photosynthetic pigments in their thylakoid membrane environment, wherein said baseline level of CRP or hsCRP prior to administration of the composition is indicative of chronic inflammation, and said effective amount comprises decreased said baseline level by least about 25% after 14 days.

### Claim 59 (depends on 58)

The method of claim 58, wherein said extract is in admixture with a physiologically acceptable carrier.

### Claim 60 (depends on 58)

The method of claim 58, wherein said baseline level is about 2 mg/L or greater.

### Claim 61 (depends on 58)

The method of claim 58, wherein said effective amount achieves a reduction of at least 50% in CRP level, or a reduction of at least 50% of hsCRP level.

### Claim 62 (depends on 61)

The method of claim 61, wherein said composition achieves a reduction of at least 60% in CRP level, or a reduction of at least 60% of hsCRP level.

### Claim 63 (depends on 62)

The method of claim 62, wherein said composition achieves a reduction of at least 77% in CRP level, or a reduction of at least 80% of hsCRP level in response to 21 days treatment.
